Research from a five-year international clinical study shows that acyclovir, a commonly prescribed drug used to suppress symptoms of the herpes virus, does not affect HIV transmission by people with both viruses.
The study, conducted by the Partners in Prevention HSV/HIV Transmission Study, was released by the New England Journal of Medicine in its online edition Jan. 20 and will follow in the print edition Feb. 4.
The largest risk group worldwide, but particularly in Africa and Asia, for contracting HIV is stable, heterosexual couples where only one partner is infected. Among those infected, about 90 percent also have a herpes simplex virus-2 (HSV-2), the most common cause of genital herpes, said study co-author Kenneth H. Fife, MD, PhD, professor of medicine in the Division of Infectious Diseases at the Indiana University School of Medicine.
"Logic indicated that outbreaks of HSV-2 sores could enhance the transmission of HIV," said Fife. "This is the first comprehensive study to look at the potential for reducing the transmission of HIV through treatment of the herpes virus."
Multiple studies have shown that frequent genital herpes recurrences increase the amount of HIV in the blood and genital tract. It is known that HIV virus is shed through genital herpes ulcers and people with those ulcers transmit HIV to other more efficiently.
Five preliminary studies showed that it is possible to decrease the amount of HIV in the blood and genital tract through treatment to suppress HSV-2. However, those studies did not measure whether there also was a reduction in HIV transmission.
The study found that acyclovir reduced the occurrence of HSV-2 genital ulcers by 73 percent and thus the amount of HIV present in the blood and genital tract decreased twofold.
In spite of the reduction of HIV present in blood levels, the researchers found there was no significant difference in the transmission of HIV. Laboratory testing showed there were 41 infections in the group taking acyclovir and 43 in the placebo group.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.